润都股份：苯磺顺阿曲库铵获得化学原料药上市申请批准通知书

Core Viewpoint - The approval of the chemical raw material drug, Benzylsuccinate Atracurium, by the National Medical Products Administration enhances the product portfolio of the company and is expected to positively impact future operating performance [1] Group 1 - The company's wholly-owned subsidiary, Rundu Jingmen, has received the approval notification for the marketing application of Benzylsuccinate Atracurium [1] - Benzylsuccinate Atracurium is indicated for use in surgical procedures and other therapeutic operations for adults and children aged one month and older, as well as for adult intensive care treatment [1] - The approval is expected to strengthen the company's market competitiveness [1]